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Abstract: Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause the
BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327). BAP1-TPDS is associated with
an increased risk of developing uveal melanoma (UM), cutaneous melanoma (CM), malignant
mesothelioma (MMe), renal cell carcinoma (RCC), meningioma, cholangiocarcinoma, multiple
non-melanoma skin cancers, and BAP1-inactivated nevi. Because of this increased risk, it is important
to identify patients with BAP1-TPDS. The associated tumors are treated by different medical disciplines,
emphasizing the need for generally applicable guidelines for initiating genetic analysis. In this
study, we describe the path to identification of BAP1-TPDS in 21 probands found in the Netherlands
and the family history at the time of presentation. We report two cases of de novo BAP1 germline
mutations (2/21, 9.5%). Findings of this study combined with previously published literature, led
to a proposal of guidelines for genetic referral. We recommend genetic analysis in patients with ≥2
BAP1-TPDS-associated tumors in their medical history and/or family history. We also propose to
test germline BAP1 in patients diagnosed with UM <40 years, CM <18 years, MMe <50 years, or
RCC <46 years. Furthermore, other candidate susceptibility genes for tumor types associated with
BAP1-TPDS are discussed, which can be included in gene panels when testing patients.
Keywords: BAP1; BAP1 tumor predisposition syndrome; germline; referral guidelines
1. Introduction
Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene underlie the
BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327) [1]. At first, somatic BAP1
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mutations were identified in 84% of 31 analyzed metastasized uveal melanoma (UM) and these
mutations were found to be associated with metastatic progression of UM [2]. In one of the patients
in this study by Harbour et al., a germline aberration in BAP1 was found. This led to the suggestion
that germline alterations in BAP1 could predispose to development of UM. The following year, a
pathogenic germline variant of BAP1 was found in a family with multiple cases of UM [3]. Between
2011 and 2013, germline BAP1 variants were also reported in association with cutaneous melanoma
(CM) [4–7], malignant mesothelioma (MMe) [5–8], and renal cell carcinoma (RCC) [9,10].
Since then, several malignancies were found to be associated with BAP1 germline pathogenic
variants, the syndrome has been termed BAP1-TPDS [3,8,11]. More recently, the list of associated
malignancies was expanded to include non-melanoma skin cancer (NMSC), meningioma, and
cholangiocarcinoma [3,12–15]. NMSC encompasses basal cell carcinomas and cutaneous squamous cell
carcinomas. Aside from malignant tumors, BAP1-inactivated nevi (BIN), previously called melanocytic
BAP1-mutated atypical intradermal tumors (MBAITs) or BAP-oma [5,16], commonly occur in patients
with BAP1-TPDS [17]. These are proliferations of atypical melanocytes deficient in BAP1 protein
expression, often with spitzoid morphology [18]. Several other malignancies have been brought in
association with BAP1-TPDS, for example: leptomeningeal melanoma [19], paraganglioma [20], and
breast carcinoma [11]. However, a correlation was not confirmed in the largest studied cohort of 181
families with BAP1-TPDS to date [12]. The penetrance of pathogenic germline BAP1 variants is high,
with 85% of BAP1-TPDS individuals being diagnosed with ≥1 tumors [12,21].
Diagnostic testing of BAP1 is needed to notify individuals carrying a pathogenic variant of BAP1
and their families of their increased cancer risk. The occurrence of loss of function variants of BAP1
in the general population is extremely low, with only 12 variants noted in gnomAD and the absence
of homozygotes [22]. However, frequency of this dominantly inherited cancer syndrome has been
reported as 1–2% of UMs [23–25], 0.5% of CMs [26], and 0–7% of MMes in unselected cases [8,27–31].
The detection of pathogenic variants in BAP1 increases to up to 25%, 0.7%, and 20% when examining
familial UM [24], CM [32], and MMe [33], respectively. The low frequency of pathogenic BAP1
variants in unselected patients with BAP1-TPDS-associated malignancies implies that guidelines for
the selection of patients with an increased risk of BAP1-TPDS are needed.
In this cohort study of BAP1-TPDS families in the Netherlands, we describe the various routes
to identification of patients with germline BAP1 pathogenic variants, their clinical phenotype, and
genotype. Based on this information and review of the literature, we propose guidelines for when to
perform genetic testing in individuals with an increased risk of having BAP1-TPDS. Moreover, a list of
candidate susceptibility genes associated with BAP1-TPDS-related malignancies is provided that can
be tested in addition to BAP1.
2. Results
2.1. Identification of BAP1-TPDS Families
In this cohort study, we describe 22 families with germline BAP1 variants, that have been identified
in the Netherlands. No clear guidelines for testing were available, but the combination of age at onset,
spectrum of tumors and family history led to the suspicion of BAP1-TPDS. Previously, families NL-1,
NL-3, NL-7, NL-12, NL-14, and NL-21 have been included in the cohort of Walpole et al. [12], but no
extensive description of the families and mode of detection was provided. The original motivation for
genetic analysis can be found in Table 1. In most cases, the analysis of the germline BAP1 status was
initiated as a result of a dermatological diagnosis. Eight of the 22 families (36%) were identified because
of the observation of BINs, which were either the single tumor type (in five individuals) or were
observed together with NMSC in the proband. Familial CM was the cause of genetic analysis in four
families. Three families (NL-14, NL-16, and NL-20) (14%) were discovered in a research setting, where
patients with familial CM were being studied. These families have been described by Potjer et al. [32].
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Adding BAP1 to the genetic analysis panel for familial CM in the Netherlands was recommended by
the authors.
Table 1. The reason for genetic testing and the phenotype of BAP1-TPDS-associated malignancies in
BAP1-variant carriers in The Netherlands.
Family
Identifier Reason for Testing Tumors Proband (Age)
BAP1-TPDS-Associated
Malignancies in Family History
(Excl. Proband)
NL-1 UM and family history of multiple UMs UM (67) UM ×3, NMSC ×2
NL-2 Multiple BINs BIN × (39 ×2)NMSC (39) UM, CM ×4, MMe ×7, NMSC ×5
NL-3 Multiple BINs BIN ×5 (29 ×5) CM, NMSC ×4
NL-4 MMe and family history of MMe MMe pt (39) CM, MMe 2×, NMSC 2×
NL-5 UM & meningioma and family historyof UM, CM, meningioma, and RCC
UM (66)
NMSC (66)
Meningioma (44)
VS (51)
UM, CM, RCC, Meningioma
NL-6 UM and family history of MMe UM (30) CM ×2, MMe, RCC, NMSC ×9
NL-7 Multiple BINs BIN ×2 (22 ×2) CM ×2, NMSC b
NL-8 CM & conjunctival melanoma
CM (49)
CoM (44)
Lung cancer (54)
CM, RCC, NMSC
NL-9 UM, MMe, and RCC
UM (57)—iris
MMe pl (61)
RCC (61)
NMSC (57)
B-cell lymphoma (58)
RCC
NL-10 Multiple BINs BIN ×2 (20, 26)NMSC (27) CM
a ×2, NMSC ×4
NL-11 Single BIN BIN (55)Breast cancer (48) UM, CM, NMSC ×13
NL-12 UM & CM
UM (53)
CM (56)
NMSC (38, 52)
CM, MMe, RCC
NL-13 Multiple BINs BIN ×4 (15 ×2, 18 ×2) -
NL-14 Familial CM b
CM ×2 (23, 27)
NMSC ×2 (50, 53)
CM ×6, NMSC ×47, metastatic
melanoma
NL-15 Multiple BINs BIN ×2 (21, 25) UM
NL-16 Familial CM b CM (65) CM ×3, RCC
NL-17 Multiple BINs BIN ×2 (14, 14) CM, RCC, Meningioma
NL-18 UM & HCC and family history of MMe& HCCs
UM (72)
HCC (68) CM
a, MMe ×3, NMSC ×5
NL-19 CM and family history of UM CM (44) UM, NMSC
NL-20 Familial CM b CM (45) CM ×3
NL-21 UM and CM UM (44)CM (55) CM
a ×3, RCC
NL-22 Familial CM
CM (47)
NMSC ×7 (54, ?)
Prostate cancer (55)
CM, NMSC ×2
a Retrospectively found in patients with wild-type (WT) germline BAP1 status, b BAP1 germline variant found in
research setting. Abreviations: UM: uveal melanoma, CM: cutaneous melanoma, MMe: malignant mesothelioma,
RCC: renal cell cancer, BIN: BAP1-inactivated nevus, NMSC: non-melanoma skin cancer (mostly basal cell
carcinomas), CoM: conjunctival melanoma, VS: vestibular schwannoma, HCC: hepatocellular carcinoma. ?: age
could not be retraced.
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The combination of cutaneous and ocular melanoma resulted in the identification of four families
(18%). The proband of family NL-8 was diagnosed with a conjunctival melanoma and five years
later, with CM. This is the first report where conjunctival melanoma has been identified in a patient
with BAP1-TPDS.
Four cases of UM in three consecutive generations triggered the ophthalmologist to refer the
proband to the clinical geneticist. Furthermore, the occurrence of UM and ≥1 non-melanoma
BAP1-TPDS-associated tumors led to the suspicion of an underlying genetic disease in four families
(18%). The last variant was discovered in a proband with peritoneal MMe and a family history of MMe.
Thus, genetic analysis was initiated as a result of the medical history of the proband in 12 cases
(55%) and the combination of medical history and family history of the proband in 10 cases (45%).
Seventeen families were referred for genetic analysis based on a dermatological diagnosis treated by a
dermatologist (n = 11), general surgeon (n = 1), a general practitioner (n = 1) and three families were
identified through research of familial CM [32]. Two cases were referred by an ophthalmologist, one by
an oncologist, and one by an internal medicine specialist. The family with variant c.437+1G>T (NL-18)
was initially referred by a surgeon based on familial hepatocellular carcinoma, and the occurrence of
UM and MMe in this family led to genetic analysis of BAP1.
2.2. BAP1 Variants in The Netherlands
In the 22 identified separate families with a germline BAP1 variant in the Netherlands, 21 unique
variants in BAP1 were observed, including 11 variants that have not been reported previously. Thirteen
germline BAP1 variants resulting in a truncated protein were found in 14 families (Table 2). It is likely
that the Dutch families, NL-10 and NL-11, with the identical BAP1 germline variant have a common
ancestor, however, no overlap in the family trees has been found.
Furthermore, six splice site variants and two missense variants in BAP1 were found (Table 3).
Splice site variant c.122+5G>C, p.? (NL-17) was classified as a variant of unknown significance (VUS),
which led to additional RNA analysis to examine the effect on RNA splicing [34,35]. The splicing of the
transcript was found to be affected by the germline variant: the donor site of exon 3 was not recognized,
which resulted in the absence of the transcript of exon 3 of the aberrant allele. The diagnostic laboratory
classified this variant as likely pathogenic based on these findings. Details of the RNA analysis can be
found as Supplementary Data S1.
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Table 2. Germline BAP1 variants causing a truncated protein.
Family
Identifier Region Germline Variant Protein Change
Chromosome Position
(GRCh37/hg19)
Pathogenicity, ACMG
Classification [36]
Previously
Published in
Previously
Reported in
NL-1 Exon 1 c.35delC p.(Pro12fs*) g.52443860del Pathogenic Walpole et al., 2019 [12]
NL-2 Exon 1 c.35_37+2delinsAGGG p.(Pro12fs*) g.52443856_52443860delinsCCCT Pathogenic New variant
NL-3 Exon 4 c.178C>T p.(Arg60*) g.52442567G>A Pathogenic Walpole et al., 2019 [12] Njauw et al., 2012 [4]Wadt et al., 2015 [36]
NL-4 Exon 4 c.182delA p.(Lys61fs*) g.52442563del Pathogenic New variant
NL-5 Exon 4 c.188_189delCT p.(Ser63fs*) g.52442556_52442557del Pathogenic New variant
NL-6 Exon 6 c.376_377delAG p.(Ser126fs*) g.52441475_52441476del Pathogenic New variant
NL-7 Exon 11 c.1017_1048del a,b p.(Gly340fs*) g.52439194_52439225del Pathogenic Walpole et al., 2019 [12]
NL-8 Exon 12 c.1153C>T p.(Arg385*) g.52438566G>A Pathogenic Njauw et al., 2012 [4]Betti et al., 2016 [37]
NL-9 Exon 13 c.1530delT p.(Ile511fs*) g.52437631del Pathogenic New variant
NL-10 Exon 13 c.1621delG p.(Val541fs*) g.52437540del Pathogenic New variant
NL-11 Exon 13 c.1621delG p.(Val541fs*) g.52437540del Pathogenic New variant
NL-12 Exon 14 c.1768C>T p.(Gln590*) g.52437276G>A Pathogenic Walpole et al., 2019 [12]
NL-13 Exon 14 c.1819delA b p.(Thr607Argfs*) g.52437225del Pathogenic New variant
NL-14 Exon 15 c.1936_1937insTT p.(Tyr646fs*) g.52436841_52436842insAA Pathogenic Walpole et al., 2019 [12]Potjer et al., 2019 [32]
a Proband also carried a familial pathogenic variant in ENG: c.1116-1117insT (p.Lys373*). b De novo mutation.
Table 3. Germline BAP1 variants in splice sites and missense variants.
Family
Identifier Region Germline Variant Protein Change
Chromosome Position
(GRCh37/hg19)
Pathogenicity, ACMG
Classification [38]
Previously
Published in Previously Reported in
NL-15 Intron 2 c.67+1G>C p.? g.52443729C>G Likely pathogenic Repo et al., 2019 [25]
NL-16 Intron 3 c.122+1G>T a p.? g.52443569C>A Likely pathogenic Potjer et al., 2019 a [32]
NL-17 Intron 3 c.122+5G>C p.? g.52443573G>C Likely pathogenic b [34] New variant
NL-18 Intron 6 c.437+1G>T p.? g.52441414C>A Likely pathogenic New variant
NL-19 Intron 8 c.660-2A>G p.? g.52440394T>C Pathogenic Walpole et al., 2019 [12]
NL-20 Intron 13 c.1730-1G>A p.? g.52437315C>T Likely pathogenic Potjer et al., 2019 [32]
NL-21 Exon 4 c.200A>G p.(Asp67Gly) g.52442545T>C Likely pathogenic [39] Walpole et al., 2019 [12] Cabaret et al., 2017 [40]
NL-22 Exon 13 c.1387C>G p.(Leu463Val) g.52437774G>C VUS New variant
a Proband also carried a (likely) pathogenic variant in BRIP1: c.894C>A, p.(Cys298*). b RNA analysis is described in Supplementary Data S1. VUS: Variant of unknown significance.
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Variant c.200A>G, p.Asp67Gly (NL-21) is located in the protein domain Peptidase C12, ubiquitin
carboxyl-terminal hydrolase 1. In silico predictions classify this variant as a VUS. Functional analysis
of the germline BAP1 variant led to the classification of this variant to be likely pathogenic [39]. This
DNA change has previously been reported by Cabaret et al. in a patient affected by multiple BINs
and a family history of mesothelioma [40]. Our patient has a medical history of UM and CM, with
a family history of RCC (Table 1). Interestingly, all the core malignancies of BAP1-TPDS are present
when combining the phenotypes of these families.
A novel missense variant c.1387C>G, p.(Leu463Val) was found in family NL-22, that was affected
by multiple cases of CM. The genetic variant was classified as a VUS by the in-silico prediction models.
However, the variant’s pathogenicity is difficult to determine without additional functional testing.
This family will be excluded from further family analyses to ensure that any drawn conclusions are
applicable to BAP1-TPDS.
Two cases of de novo mutations were found in the cohort of BAP1-TPDS families. The mutational
changes c.1017_1048del (NL-7) and c.1819delA (NL-13) in the germline BAP1 were not found in parents
and a sibling of both probands. In addition to the germline mutation in BAP1, another germline
pathogenic variant was found in the proband of NL-7. The pathogenic variant in ENG (c.1116-1117insT,
p.(Lys373*)) was inherited through the paternal lineage. Biological parenthood has been genetically
confirmed in family NL-13. The BAP1 variants are, therefore, a result of a de novo mutation, either in
the proband or one of the parents, since there is a small chance that one of the biological parents of
these probands harbors a mosaic BAP1 germline pathogenic variant.
The frequency of probable de novo mutations in our cohort of BAP1-TPDS families is 2/21 probands
(9.5%). This is the first report of the prevalence of de novo mutations found in the BAP1 gene within a
set BAP1-TPDS population, as far as we are aware. We have previously reported family NL-7 as part
of a large international cohort of BAP1-TPDS individuals [12].
2.3. Clinical Characteristics of BAP1-TPDS Families in The Netherlands
Information on clinical characteristics was available from 727 individuals from the remaining 21
families affected by a pathogenic or likely pathogenic variant in BAP1. In addition to the 21 probands,
germline BAP1 status was determined in 85 family members, of whom 41 (48%) carried a (likely)
defective BAP1 allele. This led to the identification of ten additional BAP1-TPDS individuals as obligate
carriers. A cohort of 72 carriers of germline pathogenic BAP1 variants was established.
There are slightly more female (n = 43, 60%) than male (n = 29, 40%) carriers. The median age of
18 probands at BAP1 testing was 43 years (range: 14–68). In the remaining three index patients, the
germline BAP1 variant was found after they passed away. In this study, the follow-up of the family is
completed at diagnosis of BAP1-TPDS in the proband. The malignancies found in the proband and
the family history of BAP1-TPDS-associated malignancies, before genetic analysis was performed,
are listed in Table 1. The occurrence of the BAP1-TPDS core malignancies is illustrated in Figure 1
for all probands (a) and for the BAP1-TPDS families (b). Malignancies found in probands, tested
non-proband carriers and untested members are presented in Supplementary Table S1. While most
probands only exhibited one type of BAP1-TPDS-associated malignancy, the phenotype found in the
families are more diverse.
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Figure 1. Venn diagrams of BAP1-tumor predisposition syndrome (BAP1-TPDS)-associated core
malignancies found in BAP1-TPDS probands (a) and in the 21 BAP1-TPDS families (b). Eight probands
were genetically analyzed as a result of the diagnosis of BINs and are, therefore, missing in Figure 1a.
2.4. BAP1-TPDS Core Malignancies
2.4.1. Uveal Melanoma
In our BAP1-TPDS population, nine of the 72 carriers of germline BAP1 (likely) pathogenic
variants (13%) were affected by UM. The median age at diagnosis in these patients was 61 years (range
30–72), which is similar to the median age of 66 years found in the general UM population in the
Netherlands [41].
Most (n = 7, 78%) UMs were primarily located in the posterior segment, although one patient was
diagnosed with iris melanoma. Six eyes with UM were enucleated, two tumors received ruthenium
brachytherapy and one tumor was treated with stereotactic radiotherapy. Five BAP1-TPDS patients
developed metastases from their primary UM (56%, median time to metastases from diagnosis: 24
months, range: 0.2–67 months), while four patients did not (median time since diagnosis: 25 months,
range: 21–184 months). The occurrence of UM in combination with another BAP1-TPDS-associated
malignancy was observed in three patients: other malignancies included both a RCC and a MMe in one
patient and CM in two patients. These other malignancies were all diagnosed after diagnosis of UM.
Of the untested relatives, six individuals were reported to have UM. Furthermore, four cases of
(unknown types) of ocular tumors have been listed in the family history by patients (Supplementary
Table S1).
2.4.2. Cutaneous Melanoma
CM was the most frequently diagnosed malignancy among the current cohort of BAP1-TPDS
individuals in the Netherlands, with 15 tumors occurring in 13 of the 72 carriers (21%). The median
age at diagnosis of CM in this group was 49 years of age (range 23–83). This is younger compared to
the median age of onset of 63 years in the general CM population in the Netherlands [41].
The median Breslow thickness was 1.4 mm (range: 0.34–2.8 mm), calculated from the known sizes
of 11 CMs. Metastatic disease of CM was found in three of the 13 CM patients.
Eighteen CMs were reported in untested family members. Interestingly, five CMs were found
in three tested relatives without the familial BAP1 germline aberration. These patients are, therefore,
considered to be phenocopies.
2.4.3. Malignant Mesothelioma
Eight BAP1-TPDS patients were found to have MMe (8/72 BAP1-TPDS individuals, 11%). The
median ge of onset was 60 years (range: 39–71), which is earlier than the median age of 74 years at
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diagnosis in the general Dutch population [41]. MMe was classified as pleural in six cases (75%) and
peritoneal in two cases (25%).
In untested relatives, MMe was reported in nine cases: five pleural MMe and four peritoneal
MMe. Notably, 14 of the 17 MMe patients were distributed over three families. Both family NL-4 and
family NL-18 had three cases of MMe, while eight individuals with MMe were found in family NL-2.
In the family NL-18, MMe was observed in two out of four siblings. In the family NL-2, six out of 12
siblings were diagnosed with MMe.
2.4.4. Renal Cell Carcinoma
Two of the 72 proven BAP1-TPDS patients (3%) developed RCC. They were diagnosed at 58 and
61 years of age, which is lower than the median age of 68 in the general Dutch population [41]. Both
patients also had MMe. One of the two had previously been diagnosed with UM.
2.4.5. BAP1-Inactivated Nevus
We observed 20 histologically proven excised BINs in eight BAP1-TPDS probands. The median
age of onset was 21 years of age (range: 14–55). Seven patients had two or more confirmed BINs before
diagnosis of BAP1-TPDS, with a maximum of five BINs in one patient.
2.4.6. Other Malignancies
New malignancies associated with BAP1-TPDS, as suggested by Walpole et al., include
meningioma, cholangiocarcinoma, and non-melanoma skin cancer (NMSC) [12]. No case of
cholangiocarcinoma was reported in our patient population and meningioma was present in one
proven carrier of a pathogenic BAP1 gene (1/72, 1.4%), who developed a vestibular schwannoma as
well as an UM later in life. An untested family member of this patient was also diagnosed with both
UM and meningioma.
The frequency of NMSC was substantially higher compared to meningioma and
cholangiocarcinoma, with 19 affected BAP1-TPDS patients (19/72, 26%). Most NMSC were basal cell
carcinomas, although the exact distribution of NMSC is unknown. The median age of onset was 50
years (range: 27–67). The number of tumors varied between 1 and 36, with a median of 2 NMSCs.
The described cohort in this study is too small to draw conclusions about possible associations of
other tumors types to pathogenic BAP1 variants. However, we did notice the occurrence of primary
non-cirrhotic hepatocellular carcinoma in three proven BAP1 germline variant carriers in family NL-18.
2.5. Disease-Free Survival
The disease-free survival of our included study population is plotted in Figure 2 for UM (a), CM
(b), MMe (c), and RCC (d). An event is defined as a tumor occurrence. Follow-up starts at birth,
since individuals with BAP1-TPDS are at risk of developing a malignancy from birth. The red line
illustrates the disease-free survival of non-proband BAP1-TPDS individuals. The disease-free survival
of all pathogenic BAP1 variant carriers is shown for reference (gray dotted line). Follow-up data after
the age of 65 years is unreliable, due to the limited number of non-proband germline BAP1 variant
carriers. Disease-free survival curves including and excluding the probands do not differ clearly for
UM (p = 0.19), CM (p = 0.26), MMe (p = 0.95), and RCC (p = 0.75) at the age of 65 years, as can be seen
in Figure 2.
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The cumulative disease-free proportions and their corresponding 95% confidence interval (95%
CI) were estimated at the age of 65 years, as with increasing age, estimated proportions were captured
with more uncertainty. The cumulative disease-f ee proportion at age 65 was 0.93 (95% CI 0.79–1) for
UM, 0.85 (95% CI 0.73–0.97) for CM, 0.74 (95% CI 0.54–0.95) for MMe, and 0.94 (95% CI 0.84–1) for RCC.
3. Discussion
In this study, we have described the diverse routes that led to the identification of germline BAP1
pathogenic variants in probands and relatives of 22 BAP1-TPDS families in the Netherlands. We have
found that medical history and family history led to the diagnosis of BAP1-TPDS in the described
families. Genetic analysis was most often initiated as a consequence of BINs in the medical history of
the proband. De novo germline BAP1 variants were found in families NL-7 and NL-13 (2/21, 9.5%),
in both cases, paternity was confirmed. The first presentation of these families occurred in various
medical fields, which emphasizes the need for attentive physicians to recognize potential germline
BAP1 variant carriers.
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3.1. BAP1-TPDS-Associated Malignancies
In the current study, we describe the phenotype of BAP1-TPDS families and individual BAP1
germline pathogenic variant carriers in the Netherlands at the time of presentation to the clinical
geneticist. No additional immunohistochemistry or genetic analysis of tumors in the carriers of
germline BAP1 variants has been performed. Consequently, it is uncertain if the development of
the found malignancies are correlated to the aberrant BAP1 allele. This is an interesting field for
future research.
3.1.1. Different Types of Melanomas
While UM and CM are genetically distinct malignancies, both have been established as
BAP1-TPDS-associated malignancies. Although UMs include iris melanomas, this is the first
observation of an iris melanoma in a patient with BAP1-TPDS. Scholz et al. observed somatic
mutations in GNAQ, GNA11, EIF1AX, and BAP1 (four genes that are often mutated in choroidal and
ciliary body melanomas [42]) in 19 iris melanomas [43]. When a larger cohort of 30 iris melanomas was
analyzed by Van Poppelen et al., these findings were confirmed, with additional mutations observed
in SF3B1, but also in the CM-associated genes NRAS, BRAF, PTEN, c-KIT, and TP53 [44–46]. Although
the genetic basis of iris melanomas is still being studied, iris melanoma could be considered as a
BAP1-TPDS-associated malignancy.
Conjunctival melanoma is a rare ocular malignancy occurring in the mucosal surface of the eye,
with an incidence of 0.2–0.8 per million in Caucasians [47,48]. Although conjunctival melanomas are
located on the mucosal surface of the eye, the melanomas located in the conjunctiva have been identified
as being more genetically similar to CM than UM. Mutations in the CM driver genes BRAF and NRAS
have been found in conjunctival melanoma [49,50]. The concurrence of conjunctival melanoma and
BAP1-TPDS is remarkable in light of the low prevalence of both conditions. This is the first reported
case of mucosal melanoma in association with BAP1-TPDS. However, a causal correlation is not proven
due to the absence of molecular testing or BAP1 immunohistochemical staining. This matter falls
outside the scope of this article, as tumor tissue analysis was not performed before germline BAP1
analysis. However, it is a relevant topic to explore in future studies.
Conjunctival and other mucosal melanomas have not been included in the BAP1-TPDS spectrum
and larger cohorts of BAP1-TPDS individuals need to be studied to determine a possible association.
However, one may consider these tumors as potentially BAP1-TPDS-associated malignancies when
deciding to refer a patient for genetic analysis. An alternative is to apply somatic DNA sequencing—or,
if unavailable, BAP1 immunohistochemistry—on tumor material to help decision making.
3.1.2. Mesothelial Malignancy
In the general population, MMe is located in the pleura in approximately 82% of the cases.
Previously, it has been noted that in the BAP1-TPDS population, the distribution of pleural MMe and
peritoneal MMe is more equal [33,51]. In line with previous reports, we report a higher frequency of a
peritoneal localization of MMe compared to the general population, with 11 pleural and 6 peritoneal
MMes in genotyped and ungenotyped BAP1-TPDS family members.
The majority of MMes (14 out of 17 cases) in our study occurred within three families. In two of
these families, half of a generation was affected by MMe: 2/4 siblings in NL-18 and 6/12 siblings in NL-2.
This could imply that there is a genotype–phenotype relation between the specific BAP1 aberration and
the type of malignancy. However, this does not explain the increased observed frequency in one specific
generation compared to the other generations. Furthermore, earlier reports in large BAP1-TPDS cohorts
do not support this theory [12,21]. An alternative hypothesis is a gene–environment interaction.
Development of MMe is closely associated with asbestos exposure [52,53]. When individuals
who are already more susceptible to develop MMe are exposed to asbestos, it could trigger the
oncogenesis of MMe. While this mechanism has been suggested by researchers, it has not yet
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been proven in BAP1-TPDS. However, mouse models have been established where mice harbor a
heterozygous pathogenic variant in BAP1. It has been observed that two of these mice out of a total of
93, spontaneously developed MMe [54]. MMe was found significantly more often in BAP1+/− mice
compared to the BAP1WT littermates (73% vs. 32%, respectively), when exposed to asbestos fibers.
Moreover, MMe arose in a shorter period of time in the BAP1+/− mice after initial exposure (43 weeks
vs. 55 weeks, respectively) [55]. While more research is needed in humans, this study suggests that
while spontaneous development of MMe can occur, a gene–environment interaction could possibly
explain the clustering of MMe in our BAP1-TPDS population.
3.1.3. Renal Cancer
Even though only two cases of RCC were observed, both patients also exhibited MMe in their
medical history. However, no conclusions can be drawn from this information in the described cohort.
3.1.4. Non-Melanoma Skin Tumors
The most prevalent tumors associated with BAP1-TPDS in our population are NMSCs and BINs.
BIN is a skin lesion that is closely associated with BAP1-TPDS, while the diagnosis might be missed
outside of this context, as they can be indistinguishable from ordinary dermal nevi. These melanocytic
nevi usually lack malignant characteristics clinically and can only be proven histopathologically.
Busam et al. have reported the distinct histopathologic profile of BINs: these skin tumors are
“characterized by a nevus-like silhouette and cytologic composition of large epithelioid melanocytes
with oval vesicular nuclei, distinct nucleoli, and abundant cytoplasm with well-defined cytoplasmic
borders” [56] (p. 193). Loss of nuclear BAP1 immunohistochemical staining is typical in BIN [56]. BINs
are by definition benign. Malignant transformation has been described, but is rare [7,57,58]. Because
of the predominantly benign prognosis, BIN-suspected lesions are often not removed.
Because of the high prevalence of both basal cell carcinomas and cutaneous squamous cell
carcinomas in the general population and the unfamiliarity of the generally benign BINs, the diagnosis
of BAP1-TPDS might frequently be missed. Education for dermatologists and pathologists concerning
this dermatological diagnosis is necessary to establish the correct diagnosis.
3.1.5. Tumor Frequencies Compared to International Cohorts
Nine cases of UM were found in 72 BAP1-TPDS patients (13%), 13 carriers with BAP1-TPDS were
diagnosed with CM (18%), 8 with MMe (11%), and 2 with RCC (3%), while the recent worldwide
meta-analysis found an occurrence of 25%, 20%, 20%, and 6% for UM, CM, MMe, and RCC,
respectively [12].
A possible explanation of the lower numbers found in this study could be that our patient
population is relatively young and not yet at an age to develop these malignancies. The mean age at
BAP1 germline analysis of the proband (or age at last follow-up in obligate carriers) was 44 years in the
42 carriers of a BAP1 pathogenic variant without BAP1-TPDS core malignancies and 59 years in the
remaining 27 BAP1-TPDS patients (age at BAP1 analysis is missing for three patients) that have been
diagnosed with UM, CM, MMe and/or RCC (p < 0.001). Another sign that points to age as the cause of
the discrepancy is that the frequency of CM found in our population approaches the internationally
reported frequency of CM in BAP1-TPDS. CM generally occurs at a younger age, compared to most
other malignancies [59].
It is important to note that the frequencies of malignancies are reported based on a highly selected
group of patients in both previously published articles and this study, where results are very likely to
have been influenced by bias. While our patients have not been selected following a study protocol, it
is likely that the referring physician noticed an unusually high frequency of BAP1-TPDS-associated
malignancies in the probands and/or their family history. Testing bias plays a role as well, as patients
with a previous medical history of BAP1-TPDS-associated malignancies are more likely to undergo
genetic testing.
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The clear disadvantage of using BAP1-TPDS probands for malignancy risk estimation is that these
probands are mostly tested because of the presence of a malignancy. This will give an overestimation of
malignancy risk when applied to an unselected BAP1-TPDS cohort. Therefore, we put most emphasis
on non-proband BAP1 variant carriers in the Kaplan–Meier curves. The highly selected probands
from the BAP1-TPDS families are excluded to correct for selection bias in an attempt to present more
representative frequencies of malignancies in BAP1-TPDS. However, the number of non-proband
BAP1-TPDS individuals is limited, which results in wide 95% confidence intervals. In future research,
a larger cohort is required to provide more precise estimates.
3.2. Guidelines for Referral for Genetic Analysis
As probands differ in their initial clinical presentation, it is necessary to provide guidelines that
can be applied to different medical fields. Previously, Rai et al. have made recommendations for
genetic assessment based on ≥2 BAP1-TPDS-associated tumors in the medical history and/or family
history of an individual [21]. However, carriers of a germline BAP1 pathogenic variant tend to develop
BAP1-TPDS-associated malignancies at a younger age [12,21]. This observation, combined with the
frequency of 2/21 (9.5%) of de novo mutations as reported in the current study, led to a proposal of
age-associated criteria. The proposed referral guidelines are shown in Table 4.
Table 4. Proposed referral guidelines for genetic diagnostics of BAP1-tumor predisposition syndrome
(BAP1-TPDS).
Item Referral Indicated If
Medical history ≥2 BAP1-TPDS-associated tumors a,b
Medical history and
family history
1 BAP1-TPDS-associated tumor and
first- or second-degree relative with ≥1 BAP1-TPDS-associated tumor(s) a,b
Young age of onset
• Uveal melanoma:
• Cutaneous melanoma:
• Malignant mesothelioma:
• Renal cell carcinoma:
age of onset before 40 years
age of onset before 18 years [60]
age of onset before 50 years [61]
age of onset before 46 years [62]
a BAP1-TPDS-associated tumors include: uveal melanoma, cutaneous melanoma, malignant mesothelioma, renal
cell carcinoma, meningioma, cholangiocarcinoma, BAP1-inactivated nevus. Non-melanoma skin cancer in case of
unusually high frequency in a single individual or at an unusually young age. b If cutaneous melanoma is the only
tumor type, the threshold of initiating germline BAP1 analysis should be ≥3 cutaneous melanomas in populations
with a high incidence of cutaneous melanoma.
We have adopted the recommendations made by Rai et al. concerning the medical history and
family history of BAP1-TPDS malignancies [21], and we have added age-associated criteria. Since
the publication of these recommendations, the spectrum of malignancies has expanded. One of the
added malignancies is NMSC. As NMSC occurs very frequently in the general population, we classify
non-melanoma skin cancers as a relative criterium, where referral can be considered when a high
frequency of non-melanoma skin cancers is found in a single individual or at an unusually young age.
When CM is the only BAP1-TPDS-associated malignancy present in an individual or family, the
threshold for familial CM should be ≥3 cutaneous melanomas in one individual or in the family,
given its high frequency in the general population in the Netherlands. However, in populations
where CM is less frequently found, it can be considered to uphold the criterium of ≥2 CMs. Genetic
analysis for frequently affected CM susceptibility genes, like CDKN2A and CDK4, is indicated for these
patients [32,63,64]. Testing of BAP1 should be done in parallel with testing of these susceptibility genes,
or performed subsequently in case no pathogenic variant is found.
In our study population, most of our probands (8/22, 36%) were identified as a consequence of
BINs. Interestingly, Cabaret et al. found 12 probands harboring pathogenic germline variants in BAP1
in a group of 17 (71%) patients with ≥1 BINs and a suspicious medical or family history [40]. In four
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families, BINs were the only phenotypical manifestation of BAP1-TPDS. Furthermore, Haugh et al.
performed a review of the literature and discovered that BINs were found in 40/53 individuals with
BAP1-TPDS that underwent total body inspection of the skin (75%) [65]. If a patient is diagnosed
with a single BIN, without other malignancies in their personal medical history or family history, the
criteria for germline testing are not met. However, BINs might be underdiagnosed as we have stated
previously. Therefore, it is recommended to perform immunohistochemical staining of nuclear BAP1
or somatic analysis of BAP1 in previously removed dermatological lesions to establish if germline
analysis of BAP1 is necessary.
The age-associated criteria are based on several previously published articles. Walpole et al.
showed a median age at diagnosis for UM in patients with germline null variants of 53 years
(interquartile range: 44–60 years) and a median age of 58 years for missense variants, (interquartile
range: 45–69 years) [12], which are both under the reported median age of incidental UM of 66 years
in the Netherlands [41]. Similarly, Rai et al., Haugh et al., Ewans et al., and Gupta et al. report
younger ages in patients with BAP1-TPDS [21,23,65,66]. Although this difference was not significant
when compared to control subjects by Gupta et al. (p = 0.44) and approaches significance compared
to individuals with somatic BAP1 mutations in UM (p = 0.07) [23,66]. Previously, the group from
Abdel-Rahman et al. have proposed an age-associated limit of 30 years at diagnosis of UM [3,67,68].
However, as the BAP1-TPDS patients with UM in our cohort developed UM at the age of 30 years and
older, we propose to extend this criterium to an age of onset of 40 years.
Unfortunately, due to the lack of reported studies, suggestions for the limits of young age of onset
for meningioma and cholangiocarcinoma cannot be produced. Future research is needed to provide
age-associated criteria for these malignancies. In general, future cohort studies are needed to evaluate
the efficacy of the proposed testing strategies, and adjustments in the guidelines should be made
where needed.
When applying the guidelines to the studied cohort, 21 out of the 22 described families would
have been identified. The family harboring VUS c.1387C>G, p.Leu463Val (NL-22) would not have been
genetically analyzed based on the proposed guidelines. The largest described cohort of 181 families
carrying germline BAP1 variants has been published by Walpole et al. [12]. Unfortunately, the ages at
diagnosis of malignancies and specification of family history (first-, second-, third-degree relatives)
were not described in the article. If we apply the proposed guidelines based on BAP1-TPDS-associated
malignancies to these families, assuming reported family members are first- or second-degree relatives,
120/141 (85%) families carrying null variants and 18/40 (45%) families carrying missense variants would
have been offered genetic analysis. However, none of the families with missense variants that have
been classified in the paper as having evidence towards pathogenicity would have been missed.
In the majority of families with multiple cases of one type of a BAP1-TPDS-associated malignancy,
no pathogenic germline aberration was found in BAP1. The reported frequencies of a pathogenic
germline BAP1 variant in familial UM are 20% and 25% [24,69], in familial CM 0.7% [32], and in MMe
7.7% and 20% [33,70]. In 28 families with multiple members affected by RCC, but without pathogenic
variants in the Von Hippel–Lindau gene, no pathogenic variants were found in BAP1 [71]. Possible
deep intronic variants in the BAP1 gene, not detectable with standard diagnostic techniques, might be
present in a small subset [25]. Other candidate susceptibility genes have been mentioned for most
BAP1-TPDS-associated tumors. Some are well known and strongly associated, like CDKN2A for
melanoma [72,73], while others are rare (MBD4) or more controversial, like BRCA1/2 [74–76]. These
genes require further research in larger cohorts. Meanwhile, several genes might be considered for
inclusion in gene panels, as suggested in Table 5.
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Table 5. Candidate susceptibility genes per BAP1-tumor-predisposition-syndrome-associated malignancies.
Malignancy Candidate Susceptibility Genes References
Uveal melanoma MBD4 [74,75]
Cutaneous melanoma CDKN2A , CDK4, MITF, POT1, ACD, TERF2IP, TERT [32,72,73]
Malignant mesothelioma CDKN2A , BRCA2, TMEM127, VHL, WT1 [30,37]
Renal cell carcinoma VHL, FLCN, SDHB, FH, MET, PTEN [9,77–79]
Meningioma NF2 , SMARCB1, SMARCE1, SUFU [80–84]
Cholangiocarcinoma Unknown, possibly BRCA2 [85]
3.3. Proposed Surveillance Guidelines in BAP1-TPDS
The penetrance of BAP1 germline pathogenic variants is reported to be 85% [12,21]. To
date, all studies have been performed in a highly selected group of individuals, which may
lead to an overestimation of the cancer risk. Until more information is available for BAP1-TPDS
individuals, screening for BAP1-TPDS-associated malignancies is necessary. Surveillance in BAP1-TPDS
patients could lead to early diagnosis and treatment of malignancies, which can potentially lead to
prolonged survival.
In 2014, Pilarski et al. suggested a multidisciplinary approach, recommending annual
ophthalmological and dermatological evaluations, while clear guidelines for MMe and RCC were
missing [11]. Two years later, more complete management recommendations were proposed for
families with BAP1-TPDS by the same research group [21]. In addition to the examinations by an
ophthalmologist and dermatologist, yearly physical examinations for MMe and a renal screening
protocol adjusted from the renal screening for Von Hippel–Lindau syndrome was advised (annual
abdominal ultrasound, MRI every two years). The reported ages of the youngest cases of BAP1-TPDS
with BAP1-TPDS core malignancies were 16, 25, 34, and 36 years for UM, CM, MMe, and RCC,
respectively. Initiation of the surveillance of the relevant malignancy was proposed to be 5 years before
the first reported age at diagnosis of the malignancy in association with BAP1-TPDS.
Star et al. proposed a surveillance plan for BAP1-TPDS patients [86]. Similar to prior suggestions,
they propose ophthalmological and dermatological evaluation. However, the authors advised to
decrease the period between examinations to 6 months for the skin, starting at 18 years. Similarly, they
advised to perform ocular examinations annually, starting at 16, expanding to twice a year, from the
age of 30 onwards. At that age, annual physical examination was advised, to start to look for signs of
MMe and/or RCC. Additionally, biennial radiological examination may be considered according to the
Australian colleagues. The selection of the appropriate method of imaging is complex, as the evidence
for screening in BAP1-TPDS has not been completed yet. The proposed surveillance recommendations
by Rai et al. and Star at al. are listed in Table 6 [21,86].
In order to minimize the burden for patients, all annual screening should preferably be performed
in one day, where patients are screened for BAP1-TPDS-associated malignancies by the ophthalmologist,
dermatologist, and radiologist. An experienced multidisciplinary team is necessary to manage patients
with this diverse spectrum of conditions.
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Table 6. Proposed surveillance recommendations BAP1-tumor-predisposition-syndrome-associated
malignancies.
Malignancy Surveillance as Suggested by Rai et al. [21] Surveillance as Suggested by Star et al. [86]
Uveal melanoma -Dilated eye exams andophthalmic imaging
-Starting at 11
years annually
-Dilated eye exams,
fundus photography,
and ocular ultrasound
-Starting at 16
years annually
-From 30 years
6 monthly
Cutaneous
melanoma
-Full body skin exam
and self-skin exam
-Starting at 20
years annually
-Full body skin exam
and total body
photography
-Starting at 18
years 6 monthly
Malignant
mesothelioma
-Physical examinations -Annually
-Abdominal and
respiratory
examination
-Starting at age 30
-Ultrasound exam
or MRI
-CT or MRI
-Between ages
30–55 biennially
-After the age of
55 biennially
Renal cell
carcinoma
-Ultrasound
-MRI
-Anually
-Biennially
Incorporated in mesothelioma surveillance
recommendations
4. Materials and Methods
At the Leiden University Medical Center, a multidisciplinary BAP1-TPDS outpatient clinic has
been organized for screening of carriers with BAP1-TPDS. Patients were informed about the current
study and gave consent for participation. This included written permission to review their medical
record. A collaboration was established with several medical centers in the Netherlands who provided
information from families with (likely) pathogenic germline BAP1 variants found at their center. This
study is a multicenter retrospective case series.
4.1. Clinical Mutational Data
DNA diagnostics of BAP1 were performed at the Leiden University Medical Center, Erasmus
Medical Center, University Medical Center Groningen and Radboud University Medical Center.
Data from germline BAP1 variants were obtained from the medical records. Sequencing of BAP1
was performed following the clinical protocol at each center. Reference sequence NM_004656.3 was
used to determine the Human Genome Variation Society (HGVS) nomenclature on the DNA level.
Chromosomal locations were determined using genomic build GRCh37/hg19. Interpretation of the
reported variants was performed by the above-mentioned accredited clinical genetic centers of the
Netherlands. This implies that VUS were only reported if there was a strong suspicion for possible
pathogenicity in in silico predictions.
4.2. Clinical Review
The following clinical data were collected from medical records: gender, results of genetic testing,
medical history, age at time of diagnosis of tumors and at last follow-up, family history of tumors, and
pathology reports. The medical information was collected by the treating physicians. To establish a
correct representation of BAP1-TPDS families’ phenotype at the time of genetic analysis, only tumors
that occurred prior to the diagnosis of BAP1-TPDS were included.
4.3. Survival Curves
Kaplan–Meier curves were plotted using IBM SPSS statistics 25.0, and compared with log-rank tests.
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5. Conclusions
We described a cohort of BAP1-TPDS individuals from 22 families in the Netherlands and show a
high cancer risk, in concordance with previous reports. The included families harbored 21 unique
germline BAP1 variants. A de novo BAP1 mutation was present in 9.5% of the probands. We reported
the first cases of iris melanoma and conjunctival melanoma in association with BAP1-TPDS.
The various routes to diagnosis of BAP1-TPDS have been illustrated and lead to a proposal for
referral guidelines for germline BAP1 analysis. Furthermore, alternative candidate susceptibility genes
were summarized and can be used for gene panels for patients when genetic analysis is indicated based
on young age at diagnosis or a single type of BAP1-TPDS-associated malignancy in their personal or
medical history.
Supplementary Materials: The following table is available online at http://www.mdpi.com/2072-6694/11/8/1114/s1,
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